Compare

Up to four compounds, side by side.

Useful for choosing between similar peptides or planning a stack.

Add a peptide
Attribute
GLP-1 / Glucagon Dual
Efinopegdutide
SummaryGLP-1/glucagon agonist studied primarily for fatty liver disease.
MechanismGLP-1/glucagon agonist studied primarily for fatty liver disease.
Top outcomes
  • Fat loss70
  • Inflammation70
Evidenceemerging
Half-lifeLong (days+)
Administrationsubq
Legal statusresearch only
SafetyEducational reference only. Long-term human safety varies; consult a peptide-literate clinician.
PepVault

An outcome-driven reference for modern peptides. Educational only — not medical advice, not a sales platform, not affiliated with any clinic.

Disclaimer: PepVault is an educational resource. Nothing on this site is medical advice. Many peptides discussed are research compounds and are not approved by the FDA or equivalent agencies. Always consult a qualified clinician before starting any protocol.

© 2026 PepVault